Four-Month High-Dose Rifampicin Regimens for Pulmonary Tuberculosis.

Amina Jindani,Daniel Atwine,Daniel Grint,Boubacar Bah, Jack Adams, Eduardo Rómulo Ticona,Bhabana Shrestha,Tefera Agizew,Saeed Hamid,Bushra Jamil, Adolf Byamukama,Keneth Kananura,Ivan Mugisha Taremwa,Maryline Bonnet,Lansana Mady Camara, Oumou Younoussa Bah-Sow, Kindy Sadio Bah, Nene Mamata Bah, Maimouna Sow, César Eduardo Ticona Huaroto, Raquel Mugruza Pineda, Bijesh Tandukar, Bijendra Bhakta Raya, Neko Shrestha,Anikie Mathoma, Unami P Mathebula-Modongo,Joyce Basotli,Muhammad Irfan, Dilshad Begum, Ammara Muzammil,Imran Ahmed,Rumina Hasan,Marcos V Burgos, Faisal Sultan, Mariam Hassan, Iqra Masood, Claire Robb,Jonathan Decker, Sisa Grubnic,Philip D Butcher,Adam Witney,Jasvir Dhillon,Tulika Munshi,Katherine Fielding,Thomas S Harrison

NEJM Evidence（2023）

引用 0|浏览8

暂无评分

摘要

High-Dose Rifampicin Regimen for Pulmonary TuberculosisThis randomized, controlled trial tested the efficacy and safety of high-dose rifampicin (1200 or 1800 mg/d) as part of the treatment regimen for pulmonary tuberculosis. Four-month high-dose rifampicin regimens had no dose-limiting side effects but failed to meet noninferiority criteria compared with the standard 6-month control regimen.

查看译文

关键词

pulmonary tuberculosis,four-month,high-dose

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要